RxDoctor Payments Data

Hannah Novak, PA

Internal Medicine · Bedford, PANPI 1164074639

Payments from drug & device makers

$1,163in general payments, 2019–2025

Across 46 payments — averaging $25.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$202
  • Johnson & Johnson$193
  • Actelion Pharmaceuticals US, Inc.$176
  • Inari Medical, Inc.$138
  • E.r. Squibb & Sons, L.L.C.$126
  • AstraZeneca$125
  • plus $204 from 6 others

What the payments were for

  • Food & beverage$1,163100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,163 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$20,348
Medicare patients
164
Services billed
361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$137,903
Repatha SureclickEvolocumab136$81,047
JardianceEmpagliflozin48$45,190
EntrestoSacubitril/Valsartan56$42,799
XareltoRivaroxaban51$35,377
FarxigaDapagliflozin Propanediol30$29,090
Praluent PenAlirocumab12$12,175
Atorvastatin Calcium234$3,215
Ezetimibe112$2,767
Metoprolol Succinate166$2,296
Verapamil SrVerapamil Hcl18$2,203
Verapamil ErVerapamil Hcl71$2,195
Digoxin137$1,963
Rosuvastatin Calcium93$1,817
ClopidogrelClopidogrel Bisulfate108$1,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$88$42,79956 claims
Johnson & JohnsonXarelto$193$35,37751 claims
AstraZenecaFarxiga$125$29,09030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bedford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →